| |
 Assay Development
Leveraging on comprehensive understanding in signaling pathways and cellular mechanisms in cancer biology, ARL has strong capabilities to develop primary and secondary assays of various suitable formats for cost-effective target discovery, compound screening, lead optimization and lead generation, according to established validation criteria.
ARL offers services to develop a panel of robust, single- or multi-plex in vitro and cell-based phenotypic assays for different target classes including kinases (transmembrane and cytosolic), RTKs, GPCRs, epigenetics enzymes, metabolic enzymes etc, for target discovery or lead generation, using the following methods:
- Biomolecular Interaction Assays
- Monitoring biomolecular interactions using fluorescence assays for measurement of receptor-ligand and protein-protein interactions
- Cell-Based and Phenotypic Assays
- Cellular detection in formats (96- and 384-well) including measuring cell proliferation, viability, cytotoxicity, migration and apoptosis. The analysis of reporter gene expression, fluorescent proteins, second messengers such as cAMP and Ca2+ as well as the use of reporter gene expression systems are also available
- Enzyme Activity Assays
- Enzymes are major drug targets. In particular, ARL has strong capabilities in assays for kinase, metabolic and epigenetic enzymes in various formats: radioactive, fluorescence, luminescence and scintillation proximity assay (SPA)
- DNA, RNA and Protein Levels
- Quantification of DNA, RNA and protein expression using ELISA, immunohistochemistry, flow cytometry, qPCR or bDNA
- High-Content Imaging and Flow Cytometry
- Endpoint for drug or RNAi effects on proliferation, cell cycle, apoptosis, protein localization, protein post-translational modification (phosphorylation, methylation, acetylation) and cell surface marker expression (eg. in stem cell differentiation)
|
|
